Indeed, a single‐chain antibody fragment that targets extradomain A has recently entered clinical evaluation as an scFv‐IL‐10 fusion protein for the treatment of RA (ClinicalTrials.gov ID NCT02076659). The gene discussed is IL10; the disease is rheumatoid arthritis.